RT Book, Section
A1 Kurtzman, Drew
A1 Vleugels, Ruth Ann
A1 Callen, Jeffrey
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161344743
T1 Immunosuppressive and Immunomodulatory Drugs
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK accessmedicine.mhmedical.com/content.aspx?aid=1161344743
RD 2024/04/25
AB AT-A-GLANCEImmunosuppressants  and  immunomodulators  represent  an  indispensable  group  of  antiinflammatory  medications  that  are  capable  of  treating  a  wide  array  of  inflammatory  skin  conditions.The  immunosuppressive  and  immunomodulatory  drugs  covered  in  this  chapter  include  mycophenolate  mofetil,  the  calcineurin  inhibitors  (cyclosporine,  tacrolimus,  and  pimecrolimus),  and  the  mammalian  target  of  rapamycin  (mTOR)  inhibitor  everolimus.The  primary  goal  of  therapy  with  immunosuppressants  and  immunomodulators  is  to  effectively  treat  an  inflammatory  condition  while  maintaining  patient  safety.By  working  in  an  additive  or  synergistic  fashion,  combination  regimens  have  the  potential  for  greater  efficacy  and  may  allow  for  decreased  doses  of  individual  drugs,  which  may  enhance  overall  safety  and  reduce  medication-related  side  effects.A  comprehensive  understanding  of  the  pathophysiology  of  the  disease  being  treated  as  well  as  the  pharmacokinetic  and  pharmacodynamic  properties  of  each  immunosuppressant  and  immunomodulator  is  fundamental  to  favorable  patient  outcomes.